142 related articles for article (PubMed ID: 25474585)
1. Unexpected hypotony after glaucoma drainage implant surgery associated with anti-vascular endothelial growth factor treatment.
Hoguet A; Parrish RK
JAMA Ophthalmol; 2015 Mar; 133(3):349-50. PubMed ID: 25474585
[No Abstract] [Full Text] [Related]
2. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
3. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
4. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
Freund KB; Hoang QV; Saroj N; Thompson D
Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
[TBL] [Abstract][Full Text] [Related]
5. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Schachat AP
Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
[No Abstract] [Full Text] [Related]
6. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
7. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
8. [Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].
Cervera RE; Castro V; Montero J; Torralba C; Gracia A
Arch Soc Esp Oftalmol; 2014 Jan; 89(1):42-3. PubMed ID: 24269436
[No Abstract] [Full Text] [Related]
9. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravitreal aflibercept and ranibizumab on retinal vessel diameter measured using fluorescein angiography.
Min JK; Lee S; Park JH; Woo JM; Yang HS
Acta Ophthalmol; 2018 Jun; 96(4):e546-e547. PubMed ID: 29068524
[No Abstract] [Full Text] [Related]
11. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
12. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
Scott AW; Bressler SB
Curr Opin Ophthalmol; 2013 May; 24(3):190-6. PubMed ID: 23492430
[TBL] [Abstract][Full Text] [Related]
14. Current concepts in managing wet AMD suboptimally responsive to anti-VEGF therapy.
Major JC; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(3):225-6. PubMed ID: 23676221
[No Abstract] [Full Text] [Related]
15. Aflibercept anti-vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age-related macular degeneration.
Jung JJ; Hoang QV; Arain MZ; Chang S
Acta Ophthalmol; 2016 May; 94(3):e249-50. PubMed ID: 26401896
[No Abstract] [Full Text] [Related]
16. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
Thorell MR; Nunes RP; Chen GW; Doshi RR; Dugar J; George MK; Kim BT; Lowrance MD; Modi D; Nahas Z; Gregori G; Yehoshua Z; Feuer W; Rosenfeld PJ
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):526-33. PubMed ID: 25423632
[TBL] [Abstract][Full Text] [Related]
17. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes.
Karakurt Y; Ucak T; Taslı G; Agcayazı B; İcel E; Yılmaz H
Med Sci Monit; 2018 Dec; 24():9019-9025. PubMed ID: 30542050
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
[TBL] [Abstract][Full Text] [Related]
20. Neovascular age-related macular degeneration.
Veritti D; Sarao V; Lanzetta P
Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
